key: cord-0735450-cp053nag authors: Capone, Fioravante; Ferraro, Elisabetta; Motolese, Francesco; Di Lazzaro, Vincenzo title: COVID-19 in multiple sclerosis patients treated with dimethyl fumarate date: 2021-02-20 journal: J Neurol DOI: 10.1007/s00415-021-10446-4 sha: 5c99f054879f47b1785deb8ccb3c84cbc2fe4697 doc_id: 735450 cord_uid: cp053nag nan corticosteroids (1/2), and paracetamol (2/2). No patient required hospitalization, ICU care, or oxygen support. DMF was continued during the entire course of SARS-CoV-2 infection in all patients at the usual dosage (240 mg bid). Compared with the patients presented by Mantero [1] , in our cohort average time on treatment with DMF was about 0.7 years longer, disease duration 1.8 years shorter, and two patients had significant comorbidities. Age, gender, and median EDSS were quite similar between the two groups. Notably, in our cohort, SARS-CoV-2 infection was confirmed by nasopharyngeal swab in all patients. Nowadays, there is wide discussion about the opportunity of continuing/stopping disease-modifying therapies (DMTs) in MS patients with COVID-19. The specific mechanisms of action of the various DMTs and patients' characteristics should be taken into account to individually stratify the COVID-19 risk in MS patients [2] . Theoretically, DMF could increase the COVID-19 risk because of its pleiotropic effects on the immune system including suppression of T and B cells [3, 4] and the potential induction of significant lymphopenia in a small percentage of patients [5] . On the other side, as postulated for other DMTs [6, 7] , DMF could have a protective effect by modulating the immune response to SARS-CoV-2, one of the factors associated with the clinical severity of COVID-19. Recently, Olagnier et al. [8] demonstrated that the activation of the nuclear factor erythroid-derived 2-like 2 (NRF2) pathway by agonists such as DMF induces an antiviral program, distinct from the interferon pathway, that is effective in limiting virus replication and in suppressing the inflammatory responses induced by SARS-CoV2. These experimental data suggest that DMF, not only does not increase the COVID-19 risks but it could also have a protective role against SARS-CoV-2. In this perspective, the benign course of COVID-19 observed in our case-series and in the patients described by Mantero [1] could be due, at least in part, to DMF therapy. However, the positive outcome might be unrelated to DMF, given that most patients recover spontaneously from COVID-19. In conclusion, our small case-series confirms that continuing DMF might be safe in MS patients who have normal lymphocyte count and develop mild SARS-CoV-2 infection. Available data are insufficient to draw definitive conclusions on the opportunity of continuing DMF in aged patients with significant comorbidities, lymphopenia, or severe forms of COVID-19 requiring hospitalization. Additional studies are necessary to establish the most correct management of DMF therapy in these situations and to assess if this drug can have a protective role against SARS-CoV-2 as suggested by experimental findings. Author contributions FC: contributed to the conceptualization, gathering of data, and drafting the manuscript; EF and FM: contributed to gathering of data and drafting the manuscript; VDL: contributed to drafting and revising the manuscript. Funding None. Availability of data and material (data transparency) Anonymized data will be shared with qualified external researchers, after approval of their requests. Conflicts of interest FC has received travel grants from Biogen, Merck, Sanofi-Genzyme, and Roche. EF has received travel grants from Biogen, Merck, Novartis, Sanofi-Genzyme, and Roche. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Ethics approval All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients provided consent to be anonymously included in this report. COVID-19 in dimethyl fumaratetreated patients with multiple sclerosis Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic IL-17(+) CD8(+) T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life, Spanish population The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia COVID-19 in teriflunomide-treated patients with multiple sclerosis SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate